Fasoracetam: Difference between revisions
Content deleted Content added
missing "to" |
fix 2 typos, remove subtitle of book |
||
| Line 56: | Line 56: | ||
Fasoracetam appears to agonize all three [[metabotropic glutamate receptor]]s and has improved cognitive function in rodent studies.<ref name=Connolly/> It is orally available and is excreted mostly unchanged via the urine.<ref>{{cite journal|last1=Malykh|first1=AG|last2=Sadaie|first2=MR|title=Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.|journal=Drugs|date=12 February 2010|volume=70|issue=3|pages=287-312|doi=10.2165/11319230-000000000-00000|pmid=20166767}}</ref> |
Fasoracetam appears to agonize all three [[metabotropic glutamate receptor]]s and has improved cognitive function in rodent studies.<ref name=Connolly/> It is orally available and is excreted mostly unchanged via the urine.<ref>{{cite journal|last1=Malykh|first1=AG|last2=Sadaie|first2=MR|title=Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.|journal=Drugs|date=12 February 2010|volume=70|issue=3|pages=287-312|doi=10.2165/11319230-000000000-00000|pmid=20166767}}</ref> |
||
Fasoracetam was discovered by scientists at the Japanese pharmaceutical company [[Nippon Shinyaku]], which brought it through Phase 3 clinical trials for [[vascular dementia]], and abandoned it due to lack of efficacy.<ref name=Connolly>{{cite journal |title=ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder. | volume=49(5) | journal=Ther Innov Regul Sci | pages=632-642 | last1 = Connolly| first1 = J | last2 = Glessner | first2 = J | last3 = Kao | first3 = C | last4 = Elia | first4 = J | last5 = Hakonarson | first5 = H | doi=10.1177/2168479015599811|pmid=26366330|pmc=4564067}}</ref><ref name=Hoskowitz>{{cite book|last1=Moskowitz|first1=D. H.|title=Finding the Genetic Cause and Therapy for |
Fasoracetam was discovered by scientists at the Japanese pharmaceutical company [[Nippon Shinyaku]], which brought it through Phase 3 clinical trials for [[vascular dementia]], and abandoned it due to lack of efficacy.<ref name=Connolly>{{cite journal |title=ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder. | volume=49(5) | journal=Ther Innov Regul Sci | pages=632-642 | last1 = Connolly| first1 = J | last2 = Glessner | first2 = J | last3 = Kao | first3 = C | last4 = Elia | first4 = J | last5 = Hakonarson | first5 = H | doi=10.1177/2168479015599811|pmid=26366330|pmc=4564067}}</ref><ref name=Hoskowitz>{{cite book|last1=Moskowitz|first1=D. H.|title=Finding the Genetic Cause and Therapy for ADHD, Autism and 22q|date=2017|publisher=BookBaby (self published)|isbn=9781483590981|url=https://books.google.com/books?id=LSrlDQAAQBAJ&pg=PT117|language=en}}</ref> |
||
Scientists at [[Children's Hospital of Philadelphia]] led by Hakon Hakonarson identified fasoracetam's potential use in [[attention deficit hyperactivity disorder]]<ref name=Connolly/> and Hakonarson started a company called neuroFix Therapeutics, LLC to try to bring the drug to market for this use; neuroFix acquired Nippon Shinyaku's clinical data as part of its efforts.<ref name=Hoskowitz/><ref name=Alpha/> neuroFix was acquired by |
Scientists at [[Children's Hospital of Philadelphia]] led by Hakon Hakonarson identified fasoracetam's potential use in [[attention deficit hyperactivity disorder]]<ref name=Connolly/> and Hakonarson started a company called neuroFix Therapeutics, LLC to try to bring the drug to market for this use; neuroFix acquired Nippon Shinyaku's clinical data as part of its efforts.<ref name=Hoskowitz/><ref name=Alpha/> neuroFix was acquired by Medgenics in 2015.<ref name=Alpha/> Medgenics changed its name to Aevi Genomic Medicine in 2016.<ref>{{cite web | title=Press Release: Medgenics, Inc. Announces Name Change to Aevi Genomic Medicine, Inc. | url=http://http://www.prnewswire.com/news-releases/medgenics-inc-announces-name-change-to-aevi-genomic-medicine-inc-300378599.html | publisher=Aevi via MarketWired|date=16 December 2016}}</ref> Clinical trials in adolescents with ADHD who also have mGluR mutations started in 2016.<ref name=Alpha>{{cite web | title=Medgenics: NFC-1 Could Be A Key Future Revenue Driver. | url=https://seekingalpha.com/article/4010894-medgenics-nfcminus-1-key-future-revenue-driver | author=Sharma, B.}}</ref> |
||
==References== |
==References== |
||
Revision as of 00:41, 11 June 2017
| |||
| Names | |||
|---|---|---|---|
| IUPAC name
(5R)-5-(piperidine-1-carbonyl) pyrrolidin-2-one
| |||
| Other names | |||
| Identifiers | |||
3D model (JSmol)
|
|||
| ChEMBL | |||
| ChemSpider | |||
| KEGG | |||
PubChem CID
|
|||
CompTox Dashboard (EPA)
|
|||
| |||
| |||
| Properties | |||
| C10H16N2O2 | |||
| Molar mass | 196.250 g·mol−1 | ||
| Pharmacology | |||
| Oral | |||
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |||
Fasoracetam is a research chemical of the racetam family.[3] It is a nootropic, and has been in clinical trials for vascular dementia and attention deficit hyperactivity disorder.[2][4]
Fasoracetam appears to agonize all three metabotropic glutamate receptors and has improved cognitive function in rodent studies.[5] It is orally available and is excreted mostly unchanged via the urine.[6]
Fasoracetam was discovered by scientists at the Japanese pharmaceutical company Nippon Shinyaku, which brought it through Phase 3 clinical trials for vascular dementia, and abandoned it due to lack of efficacy.[5][7]
Scientists at Children's Hospital of Philadelphia led by Hakon Hakonarson identified fasoracetam's potential use in attention deficit hyperactivity disorder[5] and Hakonarson started a company called neuroFix Therapeutics, LLC to try to bring the drug to market for this use; neuroFix acquired Nippon Shinyaku's clinical data as part of its efforts.[7][8] neuroFix was acquired by Medgenics in 2015.[8] Medgenics changed its name to Aevi Genomic Medicine in 2016.[9] Clinical trials in adolescents with ADHD who also have mGluR mutations started in 2016.[8]
References
- ^ FDA/NIH Substance registration system. Page accessed March 21, 2016
- ^ a b "Drug Profile Fasoracetam".
- ^ "5-oxo-D-prolinepiperidinamide monohydrate - Compound Summary". Retrieved 21 July 2013.
- ^ "Recommended INN List 40" (PDF). WHO Drug Information. 12 (2). 1998.
- ^ a b c Connolly, J; Glessner, J; Kao, C; Elia, J; Hakonarson, H. "ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder". Ther Innov Regul Sci. 49(5): 632–642. doi:10.1177/2168479015599811. PMC 4564067. PMID 26366330.
- ^ Malykh, AG; Sadaie, MR (12 February 2010). "Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders". Drugs. 70 (3): 287–312. doi:10.2165/11319230-000000000-00000. PMID 20166767.
- ^ a b Moskowitz, D. H. (2017). Finding the Genetic Cause and Therapy for ADHD, Autism and 22q. BookBaby (self published). ISBN 9781483590981.
- ^ a b c Sharma, B. "Medgenics: NFC-1 Could Be A Key Future Revenue Driver".
- ^ "Press Release: Medgenics, Inc. Announces Name Change to Aevi Genomic Medicine, Inc". Aevi via MarketWired. 16 December 2016.
{{cite web}}: Check|url=value (help)
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |